Meeting
2017 ASCO Annual Meeting
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
Authors
Dirk Schadendorf
University Hospital Essen, Essen, Germany
Dirk Schadendorf , Paolo Antonio Ascierto , John B. A. G. Haanen , Enrique Espinosa , Lev V. Demidov , Claus Garbe , Paul Lorigan , Helen Gogas , Christoph Hoeller , Tormod Kyrre Guren , Andree Rorive , Piotr Rutkowski , Eva Muñoz-Couselo , Reinhard Dummer , Ana Carneiro , Geke Hospers , Elena Borisovna Grigoryeva , Rafia Bhore , Paul Nathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02156804
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9524)
DOI
10.1200/JCO.2017.35.15_suppl.9524
Abstract #
9524
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).
First Author: Paolo Antonio Ascierto
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi